Drug Costs

CCF Comments to Administration’s Harmful Rebate Safe Harbor Rule

We submitted comments to the Trump Administration’s proposed regulation to eliminate the safe harbor in the federal anti-kickback law for rebates negotiated by pharmacy benefit managers (PBMs) on behalf of Medicaid managed care plans (and Medicare Part D plans).   As we have previously written, the proposed regulation raises serious concerns because it would likely […]

Clearing Up Confusion about the Medicaid Rebate Program: Part II

As federal efforts to address prescription drug costs intensifies, this three-part blog series addresses misleading claims or confusion about Medicaid, its highly effective drug rebate program and overall drug pricing issues in the hopes of better informing the debate moving forward.  Part I | Part III Aggressive negotiation and closed formularies are only one factor in […]

Clearing Up Confusion about the Medicaid Rebate Program: Part I

As federal efforts to address prescription drug costs intensify, this three-part blog series addresses misleading claims or confusion about Medicaid, its highly effective drug rebate program and overall drug pricing issues in the hopes of better informing the debate moving forward. Part II | Part III In response to federal Medicaid rebate increases, drug manufacturers would […]

Risks to Medicaid Surface in Drug Pricing Debate

As the debate over prescription drug pricing heats up, I have been worried for a while that some of the federal policy solutions being considered in Congress and in the Administration could adversely affect Medicaid and its highly effective rebate program, whether inadvertently or intentionally.  This could result in higher Medicaid drug costs, reduced beneficiary […]